Our Founder and CEO Gouze Elvire, will join Franck Riester, the French Minister Delegate for Foreign Trade and Economic Attractiveness to speak at this year’s #BIODigital, taking place on Wednesday 16th June from 16:00-16:45 EDT. Register here: bit.ly/3gdHpyQ

Did you miss our interview with our Head of Preclinical Research, Dr. Adeline Bertola, last week? Read her #QandA now: innoskel.com/interview-with… #skeletaldisorders #research #QandA

Our CEO Gouze Elvire participated in the @Pharmaceutiques #GeneTherapies webinar earlier today, where she discussed what societal, scientific, and technical challenges the sector faces in the next five years. For more information on the webinar, visit: bit.ly/3jcHu7E

We spoke to our new Chief Patient Access Officer, Dr Samantha Parker, about her career, her hopes for #InnoSkel and some of the challenges we need to overcome in the field of rare #skeletaldisorders. To read our full interview, please visit our website: bit.ly/3ideSdS

Congrats to our CEO Gouze Elvire on receiving the EY Entrepreneur Of The Year™ Southeast France 2021 Award in the #startup category, for her work transforming the treatment paradigm for patients with rare skeletal disorders. Learn more here: bit.ly/2Wq46bY

Our CEO, Gouze Elvire discusses how her entrepreneurial drive led her to become a leader in the field of #skeletaldiseases, after winning the EY Entrepreneur Of The Year™ Southeast France 2021 Award in the start-up category. See here: bit.ly/2Y3zlde

Our CPAO, Samantha Parker will be participating in the World Orphan Drug Congress congress today, where she will be chairing the cell and gene therapy session, as well as moderating the ‘Improving clinical trial design for rare diseases’ panel. Find out more: bit.ly/3oBAuCs #WODC2021

Hear from Renaud Richard, Laboratory Manager, at #InnoSkel as he discusses what attracted him to InnoSkel, his typical working day and his vision for the future of cell and gene therapy in the field of rare diseases. Read here: bit.ly/3GiWfyo #skeletaldisorders

We have appointed Sophie Amsellem-Bosq as Chief Technical Officer! Sophie brings over 20 years’ experience in cell and #genetherapy across the entire value chain from discovery through clinical development and manufacturing, up to bedside. Read here: bit.ly/3DSSWfu

We have been awarded an Innovation Passport under the UK MHRAgovuk Innovative Licensing and Access Pathway (ILAP), to pursue accelerated patient access for our first-in-class treatment for SEDc, a type II collagen disorder. See here: bit.ly/31U2yKh

Our CPAO, Sam Parker has been elected Vice Chair of the International Rare Diseases Research Consortium, a global initiative launched to tackle rare disease through research, allowing patients to receive accurate diagnosis and care. Read here: innoskel.com/innoskels-chie…

Today marks Rare Disease Day 2022! Set up by EURORDIS-Rare Diseases Europe and 65+ national alliance patient organisation partners to provide focal point that enables rare diseases advocacy work to make progress. Raise your hands with us today! rarediseaseday.org

We are proud to support #RareDiseaseDay and raise awareness of what it is like for those living with a #raredisease. Hear from individuals about what it is like living with the rare bone disorder, a type II collagen disorder, that affects bone formation and skeletal growth.

We are pleased to announce that our CEO, @elviregouze has co-authored a scientific review on the differentiation of pluripotent #stemcells published in the Journal of Bone and Mineral Research! Subscription holders can view the full paper here:asbmr.onlinelibrary.wiley.com/doi/10.1002/jb…

We are delighted to announce the appointment of Dr. Michel Detheux as Chairman of our Board of Directors. Dr. Detheux is a veteran #biotech executive with over 25 years of industry experience and is currently the co-founder, President and CEO of iTeos Therapeutics. innoskel.com/innoskel-appoi…

Our CEO, Gouze Elvire will be presenting on 17 May at this year’s Bio€quity Europe taking place in Milan next week. Would you like to speak to us about Innoskel? Contact us via the conference’s partnering platform or by email at: [email protected] #BioEquity #Conference

We will be attending the ASGCT Annual Meeting next week! Our CEO, @elviregouze will present pre-clinical data of our lead gene therapy candidate for the treatment of type II collagen disorders. Find out more here: innoskel.com/innoskel-to-pr… #ASGCT22

Our CEO @elviregouze will be presenting at the ASGCT Annual Meeting on ‘Lentiviral vector-based gene therapy for type II collagen disorders’ today at 11:00 ET as part of the Musculo-skeletal diseases session. Find out more here: annualmeeting.asgct.org #ASGCT22 #Innoskel

Great to be here at Bio€quity Europe! Our CEO, Gouze Elvire will be presenting today from 14:42-14:54 CET. See you there. To schedule a meeting contact us via the conference’s partnering platform or by email at: [email protected] #BioEquity #Conference

We have enrolled the first patient in our ROCKET observational study to evaluate type II #collagendisorders in children with short stature. Read more here: globenewswire.com/news-release/2… #ROCKETstudy #raredisease